Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
SPONSORED CONTENTLife Gets Busy, Stay ON POINT With Cytopoint®Simplify your approach to allergic pruritus with Cytopoint. Help maintain control of allergic itch when schedules get hectic for both veterinarians and pet owners alike. + Learn more
